Greenwich LifeSciences Inc
Company Profile
Business description
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
Contact
3992 Bluebonnet Drive
Building 14
StaffordTX77477
USAT: +1 832 819-3232
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
8
Stocks News & Analysis
stocks
Undervalued ASX retailer benefiting from rebound in spending
stocks
Undervalued ASX share searches for cost savings
stocks
Chart of the Week: Where we see opportunities after year end market sell-off
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,983.30 | 28.90 | 0.32% |
| CAC 40 | 8,068.62 | 17.14 | -0.21% |
| DAX 40 | 24,186.49 | 108.12 | -0.45% |
| Dow JONES (US) | 48,458.05 | 245.96 | -0.51% |
| FTSE 100 | 9,649.03 | 54.13 | -0.56% |
| HKSE | 25,976.79 | 446.28 | 1.75% |
| NASDAQ | 23,195.17 | 398.69 | -1.69% |
| Nikkei 225 | 50,836.55 | 687.73 | 1.37% |
| NZX 50 Index | 13,406.91 | 11.04 | 0.08% |
| S&P 500 | 6,827.41 | 73.59 | -1.07% |
| S&P/ASX 200 | 8,697.30 | 32.40 | 0.37% |
| SSE Composite Index | 3,889.35 | 16.03 | 0.41% |